ArticleBMC endocrine disorders2026
Association between endothelial activation and stress index and mortality in critically ill patients with diabetes mellitus: a retrospective cohort study.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe Endothelial Activation and Stress Index (EASIX) serves as a biomarker of endothelial dysfunction. Although EASIX is prognostic in critical illnesses such as sepsis, its specific association with mortality in critically ill patients with diabetes mellitus (DM) is undetermined. This study was designed to evaluate this relationship.
methodsThis retrospective study utilized data from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. EASIX was calculated as lactate dehydrogenase (U/L) × creatinine (mg/dL) / platelet count (10⁹/L) and analyzed as log2-transformed values and by tertiles. The primary outcome was 30-day mortality, with 365-day mortality as a secondary outcome. Cox proportional hazards regression, Kaplan-Meier analysis, restricted cubic splines, subgroup analyses, and mediation analysis with lactate as a mediator were employed to evaluate the prognostic association. Sensitivity analyses, including propensity score matching, were performed to assess the robustness of the findings.
resultsThis study included 4,175 critically ill patients with DM. After full adjustment, each log2‑unit increase in the EASIX score was associated with a significantly increased risk of both 30‑day mortality (HR 1.20, 95% CI 1.16-1.24) and 365‑day mortality (HR 1.14, 95% CI 1.11-1.17). Mortality risk demonstrated a graded increase across ascending EASIX tertiles. A linear dose‑response relationship was confirmed, and this association remained consistent across most predefined subgroups. Propensity score matching analysis further supported this association. Mediation analysis indicated that lactate levels partially mediated the observed relationship between EASIX and mortality.
conclusionsEASIX is independently associated with increased 30‑day and 365‑day mortality in critically ill patients with DM, an effect partially mediated by lactate. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.